Evidence map›Paper›PMID 30514916›Full record

ArticleScientific reports2018

Extracellular vesicles produced in B cells deliver tumor suppressor miR-335 to breast cancer cells disrupting oncogenic programming in vitro and in vivo.

Gonzalo Almanza, Jeffrey J Rodvold, Brian Tsui, Kristen Jepsen, Hannah Carter, Maurizio Zanetti

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Delivery of miR-214 via extracellular vesicles downregulatesExtracellular vesicles and circulating nucleic acids · 2024
    Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Gonzalo AlmanzaThe Laboratory of Immunology, Department of Medicine and Moores Cancer Center, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA, 92093-0815, USA.
Jeffrey J RodvoldThe Laboratory of Immunology, Department of Medicine and Moores Cancer Center, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA, 92093-0815, USA.
Brian TsuiDivision of Medical Genetics, Department of Medicine, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA, 92093, USA.ORCID http://orcid.org/0000-0001-8017-5895
Kristen JepsenIGM Genomics Center, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA, 92093, USA.
Hannah CarterDivision of Medical Genetics, Department of Medicine, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA, 92093, USA.ORCID http://orcid.org/0000-0002-1729-2463
Maurizio ZanettiThe Laboratory of Immunology, Department of Medicine and Moores Cancer Center, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA, 92093-0815, USA. mzanetti@ucsd.edu.
University of California San Diego · US

Funding

Targeting Cancer miRNAs by Adoptive Transfer of Programmed B LymphocytesR21CA178674 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ZANETTI, MAURIZIO · 2014 to 2015
$371k
DH | NIHR | Research Trainees Coordinating Centre (NIHR Research Trainees Coordinating Centre) R21CA178674
6 · The paper itself

Abstract

The successful implementation of miRNA (miR) therapies in humans will ultimately rely on the use of vehicles with improved cellular delivery capability. Here we tested a new system that leverages extracellular vesicles (EVs) laden with a tumor suppressor miRNA (miR-335) produced in B cells by plasmid DNA induction (iEVs). We demonstrate that iEVs-335 efficiently and durably restored the endogenous miR-335 pool in human triple negative breast cancer cells, downregulated the expression of the miR-335 target gene SOX4 transcription factor, and markedly inhibited tumor growth in vivo. Remarkably, iEVs-335 mediated transcriptional effects that persisted in tumors after 60 days post orthotopic implantation. Genome-wide RNASeq analysis of cancer cells treated in vitro with iEVs-335 showed the regulation of a discrete number of genes only, without broad transcriptome perturbations. This new technology may be ideally suited for therapies aimed to restore tumor suppressor miRNAs in cancer cells, disrupting the oncogenic program established after escape from miRNA control.

Indexed as

AnimalsB-LymphocytesCarcinogenesisCell Line, TumorExtracellular VesiclesGene Expression Regulation, NeoplasticGenes, Tumor SuppressorHumansMiceMice, Inbred NODMicroRNAsSignal TransductionSOXC Transcription FactorsTriple Negative Breast NeoplasmsXenograft Model Antitumor AssaysMicroRNAsMIRN335 microRNA, humanSOX4 protein, humanSOXC Transcription Factors

Identifiers

PMID30514916
PMCPMC6279829
OpenAlexW2902222153

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.